All In Biotech

Drug Trial Radar · NCT06581783

Impact of Timing of Premedication on Mucosal Visibility During Endoscopy-A Randomized Controlled Trial

Impact of Timing of Premedication on Mucosal Visibility During Endoscopy

Last checked: Nov 20, 2026Latest source record: May 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,200

Actual

Start

Dec 1, 2024

Primary completion

Feb 18, 2025

Study completion Apr 29, 2025

Sponsor

Lead sponsor
Asian Institute of Gastroenterology, IndiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

UGI endoscopy(esophagogastroduodenoscopy) is the main diagnostic modality for direct visualization ,real time assessment and interpretation of findings encountered. The evaluation of esophagogastroduodenoscopy (EGD) quality measures encompasses several categories, such as structure, procedure, result, and adverse events. The peri-EGD period procedures fall under the procedural area, which is primarily concerned with preventing and minimising missed diagnoses. . More aid in the identification and characterisation of gastrointestinal mucosal lesions is provided by endoscopes equipped with improved imaging technologies, such as multiband or narrow-band imaging (NBI). Despite these advancements of technological aspects, the unclean mucosal surface of the stomach can make these high-end pieces of equipment virtually useless To visualize properly and diagnose accurately there should be clear visibility of mucus apart from operator experience. Since the stage at diagnosis of upper gastrointestinal cancer is a major factor in survival, early detection is essential in improving the prognosis of patients the main factors responsible for hinderance of mucosal visibility are mucus foam and bubbles, which requires additional care for the clearance to enhance the vision and also decrease endoscopy duration by alleviating the need of repeated flushing and suctioning during endoscopy. The froth and bubbles are made of mucous secretions mixed with gastric juice and bile. Simethicone (polydimethylsiloxane and silicon dioxide) has been proven to be a promising defoaming agent as an endoscopic premedication in removing bubbles . Simethicone works by reducing the surface tension of air bubbles, and releases the trapped air by causing small bubbles to coalesce and collapse . N-acetylcysteine (nac), a mucolytic agent, has also been used as premedication acts by removing the mucous overlying the gastrointestinal mucosa 4-point scale described by Basford et al 1. No adherent mucus and clear views of the mucosa. 2. A thin coating of mucus that did not obscure views of the mucosa. 3. Some mucus/bubbles partially obscuring views of the mucosa (i. E. A small mucosal lesion might be missed without flushing 4. Heavy mucus/bubbles obscuring views of the mucosa (i. E. Extensive flushing is needed to avoid missing small mucosal lesions)

Conditions

  • Endoscopy, Digestive System

Interventions

  • Simethicone plus NACDrug

    Drug simethicone plus N acetylcysteine will be given before endoscopy with different time intervals

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. comparison of mucosal visibility between 4 groupsTime frame: 10-30 minutes

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asian Institute of Gastroenterology /Aig Hospitals

    Hyderabad, Telangana, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.